Toxocara	B-OG
canis	I-OG
:	O
Molecular	O
basis	O
of	O
immune	O
recognition	O
and	O
evasion	O

Toxocara	B-OG
canis	I-OG
has	O
extraordinary	O
abilities	O
to	O
survive	O
for	O
many	O
years	O
in	O
the	O
tissues	O
of	O
diverse	O
vertebrate	O
species	O
,	O
as	O
well	O
as	O
to	O
develop	O
to	O
maturity	O
in	O
the	O
intestinal	O
tract	O
of	O
its	O
definitive	O
canid	B-OG
host	O
.	O

Human	B-OG
disease	O
is	O
caused	O
by	O
larval	O
stages	O
invading	O
musculature	O
,	O
brain	O
and	O
the	O
eye	O
,	O
and	O
immune	O
mechanisms	O
appear	O
to	O
be	O
ineffective	O
at	O
eliminating	O
the	O
infection	B-DS
.	O

Survival	O
of	O
T	B-OG
.	I-OG
canis	I-OG
larvae	O
can	O
be	O
attributed	O
to	O
two	O
molecular	O
strategies	O
evolved	O
by	O
the	O
parasite	O
.	O

Firstly	O
,	O
it	O
releases	O
quantities	O
of	O
‘	O
excretory	O
–	O
secretory	O
’	O
products	O
which	O
include	O
lectins	B-GP
,	O
mucins	B-GP
and	O
enzymes	O
that	O
interact	O
with	O
and	O
modulate	O
host	O
immunity	O
.	O

For	O
example	O
,	O
one	O
lectin	B-GP
(	O
CTL	B-GP
-	I-GP
1	I-GP
)	O
is	O
very	O
similar	O
to	O
mammalian	O
lectins	B-GP
,	O
required	O
for	O
tissue	O
inflammation	O
,	O
suggesting	O
that	O
T	B-OG
.	I-OG
canis	I-OG
may	O
interfere	O
with	O
leucocyte	O
extravasation	O
into	O
infected	O
sites	O
.	O

The	O
second	O
strategy	O
is	O
the	O
elaboration	O
of	O
a	O
specialised	O
mucin	B-GP
-	O
rich	O
surface	O
coat	O
;	O
this	O
is	O
loosely	O
attached	O
to	O
the	O
parasite	O
epicuticle	O
in	O
a	O
fashion	O
that	O
permits	O
rapid	O
escape	O
when	O
host	O
antibodies	O
and	O
cells	O
adhere	O
,	O
resulting	O
in	O
an	O
inflammatory	O
reaction	O
around	O
a	O
newly	O
vacated	O
focus	O
.	O

The	O
mucins	B-GP
have	O
been	O
characterised	O
as	O
bearing	O
multiple	O
glycan	O
side	O
-	O
chains	O
,	O
consisting	O
of	O
a	O
blood	O
-	O
group	O
-	O
like	O
trisaccharide	O
with	O
one	O
or	O
two	O
O	O
-	O
methylation	O
modifications	O
.	O

Both	O
the	O
lectins	B-GP
and	O
these	O
trisaccharides	O
are	O
targeted	O
by	O
host	O
antibodies	O
,	O
with	O
anti	O
-	O
lectin	B-GP
antibodies	O
showing	O
particular	O
diagnostic	O
promise	O
.	O

Antibodies	O
to	O
the	O
mono	O
-	O
methylated	O
trisaccharide	O
appear	O
to	O
be	O
T	B-OG
.	I-OG
canis	I-OG
-	O
specific	O
,	O
as	O
this	O
epitope	O
is	O
not	O
found	O
in	O
the	O
closely	O
related	O
Toxocara	B-OG
cati	I-OG
,	O
but	O
all	O
other	O
antigenic	O
determinants	O
are	O
very	O
similar	O
between	O
the	O
two	O
species	O
.	O

This	O
distinction	O
may	O
be	O
important	O
in	O
designing	O
new	O
and	O
more	O
accurate	O
diagnostic	O
tests	O
.	O

Further	O
tools	O
to	O
control	O
toxocariasis	B-DS
could	O
also	O
arise	O
from	O
understanding	O
the	O
molecular	O
cues	O
and	O
steps	O
involved	O
in	O
larval	O
development	O
.	O
In	O
vitro	O
-	O
cultivated	O
larvae	O
express	O
high	O
levels	O
of	O
four	O
mRNAs	O
that	O
are	O
translationally	O
silenced	O
,	O
as	O
the	O
proteins	O
they	O
encode	O
are	O
not	O
detectable	O
in	O
cultured	O
larvae	O
.	O

However	O
,	O
these	O
appear	O
to	O
be	O
produced	O
once	O
the	O
parasite	O
has	O
entered	O
the	O
mammalian	O
host	O
,	O
as	O
they	O
are	O
recognised	O
by	O
specific	O
antibodies	O
in	O
infected	O
patients	O
.	O

Elucidating	O
the	O
function	O
of	O
these	O
genes	O
,	O
or	O
analysing	O
if	O
micro	O
-	O
RNA	O
translational	O
silencing	O
suppresses	O
production	O
of	O
the	O
proteins	O
,	O
may	O
point	O
towards	O
new	O
drug	O
targets	O
for	O
tissue	O
-	O
phase	O
parasites	B-OG
in	O
humans	B-OG
.	O

Introduction	O

Toxocara	B-OG
canis	I-OG
is	O
the	O
most	O
prevalent	O
intestinal	O
roundworm	B-OG
of	O
dogs	B-OG
,	O
foxes	B-OG
and	O
other	O
canid	B-OG
species	O
,	O
with	O
zoonotic	O
potential	O
for	O
human	B-OG
beings	O
.	O

In	O
many	O
temperate	O
countries	O
,	O
toxocariasis	B-DS
is	O
the	O
most	O
common	O
helminth	B-DS
infection	I-DS
and	O
causes	O
a	O
significant	O
morbidity	O
(	O
Despommier	O
,	O
2003	O
;	O
Hotez	O
and	O
Wilkins	O
,	O
2009	O
;	O
Rubinsky	O
-	O
Elefant	O
et	O
al	O
.,	O
2010	O
;	O
Smith	O
et	O
al	O
.,	O
2009	O
).	O

The	O
nematode	B-OG
has	O
many	O
salient	O
biological	O
features	O
,	O
which	O
contribute	O
to	O
its	O
continuing	O
presence	O
in	O
animal	B-OG
and	O
human	B-OG
populations	O
.	O

Firstly	O
,	O
it	O
is	O
able	O
to	O
invade	O
an	O
extraordinarily	O
wide	O
range	O
of	O
hosts	O
,	O
from	O
invertebrates	O
and	O
poultry	O
(	O
Galvin	O
,	O
1964	O
)	O
through	O
to	O
mice	B-OG
and	O
man	B-OG
(	O
Strube	O
et	O
al	O
.,	O
2013	O
);	O
for	O
all	O
but	O
the	O
definitive	O
(	O
canid	B-OG
)	O
species	O
,	O
these	O
represent	O
intermediate	O
hosts	O
which	O
can	O
,	O
through	O
predation	O
,	O
allow	O
the	O
parasite	O
to	O
reach	O
its	O
final	O
definitive	O
host	O
species	O
.	O

Secondly	O
,	O
the	O
larval	O
stage	O
is	O
able	O
to	O
enter	O
a	O
long	O
-	O
term	O
developmental	O
arrest	O
,	O
which	O
allows	O
it	O
to	O
suspend	O
life	O
cycle	O
progression	O
whilst	O
in	O
a	O
paratenic	O
host	O
,	O
and	O
to	O
resume	O
maturation	O
to	O
the	O
adult	O
stage	O
only	O
once	O
reaching	O
a	O
canid	B-OG
species	O
.	O

Thirdly	O
,	O
even	O
in	O
female	O
canids	B-OG
,	O
developmental	O
arrest	O
occurs	O
so	O
that	O
larvae	O
can	O
dwell	O
in	O
tissues	O
until	O
pregnancy	O
occurs	O
,	O
and	O
then	O
migrate	O
transplacentally	O
or	O
via	O
colostrum	O
to	O
infect	O
the	O
foetal	O
or	O
newborn	O
pup	O
(	O
Schnieder	O
et	O
al	O
.,	O
2011	O
).	O

T	B-OG
.	I-OG
canis	I-OG
is	O
highly	O
prevalent	O
in	O
all	O
canid	B-OG
populations	O
that	O
are	O
not	O
treated	O
regularly	O
with	O
anthelmintics	O
,	O
and	O
its	O
infectivity	O
to	O
wild	O
species	O
renders	O
elimination	O
almost	O
impossible	O
.	O

Furthermore	O
,	O
the	O
arrested	O
state	O
has	O
remarkable	O
longevity	O
:	O
in	O
experimentally	O
infected	O
monkeys	B-OG
for	O
example	O
,	O
larvae	O
remained	O
viable	O
in	O
the	O
tissues	O
for	O
9	O
years	O
and	O
were	O
able	O
to	O
infect	O
mice	B-OG
on	O
transfer	O
(	O
Beaver	O
,	O
1962	O
).	O

Within	O
the	O
paratenic	O
host	O
,	O
T	B-OG
.	I-OG
canis	I-OG
larvae	O
can	O
migrate	O
widely	O
including	O
the	O
liver	O
,	O
musculature	O
and	O
the	O
central	O
nervous	O
system	O
,	O
causing	O
the	O
well	O
-	O
characterised	O
syndrome	O
of	O
visceral	B-DS
larva	I-DS
migrans	I-DS
(	O
VLM	B-DS
)	O
(	O
Beaver	O
et	O
al	O
.,	O
1952	O
;	O
Carvalho	O
and	O
Rocha	O
,	O
2011	O
;	O
Schantz	O
,	O
1989	O
).	O

The	O
propensity	O
to	O
invade	O
the	O
brain	O
and	O
the	O
eye	O
has	O
given	O
rise	O
to	O
particular	O
concern	O
in	O
the	O
human	B-OG
population	O
,	O
with	O
ocular	B-DS
toxocariasis	I-DS
(	O
OT	B-DS
)	O
a	O
recognised	O
syndrome	O
(	O
Good	O
et	O
al	O
.,	O
2004	O
),	O
and	O
neurotoxocariasis	B-DS
(	O
NT	B-DS
)	O
inferred	O
from	O
cognitive	B-DS
deficits	I-DS
,	O
higher	O
prevalence	O
among	O
epilepsy	B-DS
cases	O
(	O
Quattrocchi	O
et	O
al	O
.,	O
2012	O
),	O
and	O
finding	O
larvae	O
in	O
post	O
-	O
mortem	O
brain	O
samples	O
(	O
Hill	O
et	O
al	O
.,	O
1985	O
).	O

Current	O
options	O
for	O
treatment	O
of	O
humans	B-OG
infected	O
with	O
tissue	O
-	O
dwelling	O
larvae	O
are	O
of	O
uncertain	O
efficacy	O
because	O
of	O
the	O
covert	O
nature	O
of	O
the	O
infection	B-DS
and	O
the	O
incomplete	O
resolution	O
of	O
symptoms	O
(	O
Othman	O
,	O
2012	O
;	O
Wiśniewska	O
-	O
Ligier	O
et	O
al	O
.,	O
2012	O
).	O

Immune	O
recognition	O

Pathogens	O
are	O
recognised	O
initially	O
by	O
the	O
innate	O
immune	O
system	O
reacting	O
to	O
intrinsically	O
foreign	O
molecular	O
signatures	O
associated	O
with	O
xenogeneic	O
species	O
,	O
such	O
as	O
bacterial	O
lipopolysaccharide	O
,	O
unmethylated	O
DNA	O
and	O
fungal	O
carbohydrates	O
.	O

Such	O
signals	O
are	O
essential	O
for	O
innate	O
immune	O
sentinel	O
cells	O
,	O
such	O
as	O
dendritic	O
cells	O
,	O
to	O
react	O
to	O
the	O
presence	O
of	O
infectious	O
organisms	O
and	O
to	O
initiate	O
pathogen	O
-	O
specific	O
responses	O
from	O
the	O
adaptive	O
immune	O
system	O
.	O

Currently	O
,	O
few	O
such	O
“	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
”	O
(	O
PAMPs	O
)	O
have	O
been	O
defined	O
for	O
any	O
helminth	B-OG
parasite	O
,	O
but	O
their	O
existence	O
in	O
T	B-OG
.	I-OG
canis	I-OG
can	O
be	O
surmised	O
by	O
the	O
strong	O
adaptive	O
immune	O
response	O
that	O
occurs	O
in	O
this	O
infection	B-DS
.	O

The	O
major	O
feature	O
of	O
this	O
adaptive	O
immune	O
response	O
is	O
production	O
of	O
T	B-OG
.	I-OG
canis	I-OG
-	O
specific	O
antibodies	O
,	O
associated	O
with	O
CD4	B-GP
+	O
T	O
-	O
helper	O
type	O
2	O
cell	O
(	O
Th2	O
)	O
activity	O
(	O
Del	O
Prete	O
et	O
al	O
.,	O
1991	O
).	O

Such	O
a	O
Th2	O
response	O
is	O
characterised	O
by	O
release	O
of	O
a	O
specific	O
subset	O
of	O
mediators	O
,	O
in	O
particular	O
the	O
type	B-GP
2	I-GP
cytokines	I-GP
IL	B-GP
-	I-GP
4	I-GP
,	O
-	O
5	O
,	O
-	O
10	O
and	O
-	O
13	O
,	O
during	O
infection	B-DS
.	O

Subsequently	O
,	O
IL	B-GP
-	I-GP
4	I-GP
promotes	O
B	O
cell	O
differentiation	O
and	O
antibody	O
class	O
-	O
switching	O
,	O
while	O
IL	B-GP
-	I-GP
5	I-GP
drives	O
the	O
differentiation	O
of	O
eosinophils	O
,	O
a	O
marked	O
feature	O
of	O
human	B-OG
Toxocara	B-DS
spp	I-DS
.	I-DS
infection	I-DS
(	O
Beaver	O
et	O
al	O
.,	O
1952	O
).	O

T	O
cell	O
responses	O
to	O
T	B-OG
.	I-OG
canis	I-OG
in	O
human	B-OG
beings	O
are	O
clearly	O
of	O
the	O
Th2	O
type	O
,	O
and	O
are	O
stimulated	O
by	O
the	O
“	O
excretory	O
–	O
secretory	O
”	O
(	O
ES	O
)	O
antigens	O
of	O
the	O
parasite	O
(	O
Del	O
Prete	O
et	O
al	O
.,	O
1991	O
).	O

However	O
,	O
no	O
individual	O
T	O
cell	O
specific	O
antigen	O
or	O
epitope	O
has	O
yet	O
been	O
defined	O
from	O
T	B-OG
.	I-OG
canis	I-OG
.	O

Recently	O
,	O
the	O
distinction	O
between	O
innate	O
and	O
adaptive	O
arms	O
of	O
immunity	O
has	O
become	O
much	O
more	O
blurred	O
with	O
identification	O
of	O
innate	O
lymphoid	O
cells	O
,	O
which	O
can	O
rapidly	O
produce	O
Type	B-GP
-	I-GP
2	I-GP
cytokines	I-GP
(	O
Neill	O
et	O
al	O
.,	O
2010	O
)	O
without	O
requiring	O
activation	O
by	O
dendritic	O
cells	O
(	O
Smith	O
et	O
al	O
.,	O
2012	O
).	O

Indeed	O
,	O
it	O
has	O
been	O
known	O
for	O
some	O
time	O
that	O
some	O
innate	O
populations	O
of	O
cells	O
can	O
participate	O
in	O
the	O
“	O
Th2	O
response	O
”	O
to	O
T	B-OG
.	I-OG
canis	I-OG
,	O
for	O
example	O
non	O
-	O
B	O
-	O
non	O
-	O
T	O
cells	O
produce	O
IL	B-GP
-	I-GP
5	I-GP
,	O
even	O
in	O
T	O
cell	O
-	O
deficient	O
nude	B-OG
mice	I-OG
infected	O
with	O
the	O
parasite	O
(	O
Takamoto	O
et	O
al	O
.,	O
1995	O
).	O

Moreover	O
,	O
eosinophilia	B-DS
in	O
infected	O
mice	B-OG
shows	O
a	O
biphasic	O
response	O
with	O
early	O
(	O
day	O
10	O
)	O
and	O
late	O
(	O
day	O
21	O
)	O
peaks	O
;	O
while	O
the	O
later	O
peak	O
is	O
absent	O
in	O
CD4	B-GP
+	O
T	O
cell	O
-	O
deficient	O
mice	B-OG
,	O
the	O
earlier	O
one	O
is	O
intact	O
,	O
indicating	O
that	O
it	O
is	O
generated	O
by	O
the	O
innate	O
rather	O
than	O
the	O
adaptive	O
Type	O
-	O
2	O
response	O
(	O
Takamoto	O
et	O
al	O
.,	O
1998	O
).	O

Generation	O
of	O
specific	O
antibodies	O
provides	O
the	O
most	O
definitive	O
evidence	O
for	O
infection	B-DS
and	O
is	O
the	O
basis	O
for	O
all	O
diagnostic	O
tests	O
for	O
toxocariasis	B-DS
;	O
with	O
ELISA	O
and	O
Western	O
blot	O
reactivity	O
to	O
T	B-OG
.	I-OG
canis	I-OG
ES	O
(	O
TES	O
)	O
antigens	O
generally	O
employed	O
.	O

However	O
,	O
the	O
diagnostic	O
field	O
is	O
still	O
evolving	O
with	O
respect	O
to	O
the	O
optimal	O
target	O
antigens	O
that	O
should	O
be	O
used	O
,	O
and	O
more	O
critically	O
to	O
the	O
interpretation	O
of	O
antibody	O
reactivity	O
to	O
an	O
infection	B-DS
which	O
is	O
frequently	O
covert	O
and	O
in	O
which	O
symptoms	O
do	O
not	O
necessarily	O
correlate	O
with	O
infection	B-DS
intensity	O
or	O
antibody	O
titre	O
(	O
Smith	O
et	O
al	O
.,	O
2009	O
).	O

There	O
are	O
now	O
extensive	O
data	O
on	O
the	O
seroprevalence	O
of	O
anti	O
-	O
TES	O
antibodies	O
in	O
human	B-OG
populations	O
around	O
the	O
world	O
,	O
using	O
the	O
established	O
ELISA	O
.	O

In	O
older	O
studies	O
,	O
seropositivity	O
in	O
Europe	O
ranged	O
from	O
3	O
to	O
7	O
%	O
in	O
adults	O
and	O
7	O
to	O
23	O
%	O
in	O
children	O
(	O
Gillespie	O
et	O
al	O
.,	O
1993	O
),	O
while	O
in	O
the	O
USA	O
13	O
.	O
9	O
%	O
of	O
those	O
over	O
6	O
years	O
of	O
age	O
were	O
antibody	O
-	O
positive	O
(	O
Won	O
et	O
al	O
.,	O
2008	O
).	O

Remarkably	O
,	O
seroprevalences	O
exceeded	O
50	O
%	O
in	O
tropical	O
settings	O
such	O
as	O
the	O
Caribbean	O
(	O
Bundy	O
et	O
al	O
.,	O
1987	O
;	O
Magnaval	O
et	O
al	O
.,	O
1994	O
).	O

More	O
recent	O
studies	O
similarly	O
report	O
seroprevalences	O
of	O
14	O
.	O
5	O
%	O
in	O
Polish	O
teenagers	O
(	O
Jarosz	O
et	O
al	O
.,	O
2010	O
),	O
13	O
%	O
in	O
Turkish	O
children	O
(	O
Doğan	O
et	O
al	O
.,	O
2007	O
)	O
and	O
9	O
%	O
in	O
Iranian	O
under	O
-	O
10s	O
(	O
Fallah	O
et	O
al	O
.,	O
2007	O
),	O
rising	O
to	O
27	O
%	O
in	O
Brazilian	O
Amazonia	O
(	O
Rubinsky	O
-	O
Elefant	O
et	O
al	O
.,	O
2008	O
)	O
and	O
45	O
–	O
82	O
%	O
in	O
different	O
rural	O
districts	O
of	O
Sulawesi	O
,	O
Indonesia	O
(	O
Hayashi	O
et	O
al	O
.,	O
2005	O
).	O

Hence	O
widespread	O
toxocariasis	B-DS
remains	O
of	O
great	O
concern	O
in	O
most	O
parts	O
of	O
the	O
world	O
.	O

The	O
question	O
of	O
which	O
serum	O
antibody	O
isotypes	O
are	O
most	O
relevant	O
still	O
remains	O
to	O
be	O
explored	O
.	O

Most	O
human	B-OG
infections	B-DS
generate	O
antibodies	O
of	O
the	O
IgG1	B-GP
subclass	O
,	O
with	O
significant	O
levels	O
of	O
both	O
IgM	B-GP
and	O
IgE	B-GP
(	O
Smith	O
,	O
1993	O
).	O

The	O
IgG4	B-GP
isotype	O
,	O
which	O
can	O
be	O
predominant	O
in	O
other	O
,	O
more	O
intense	O
,	O
tissue	O
helminth	B-DS
infections	I-DS
such	O
as	O
filariasis	B-DS
and	O
schistosomiasis	B-DS
(	O
Maizels	O
et	O
al	O
.,	O
1995	O
)	O
is	O
less	O
prominent	O
,	O
although	O
reportedly	O
more	O
evident	O
in	O
active	O
cases	O
of	O
visceral	B-DS
larva	I-DS
migrans	I-DS
(	O
Obwaller	O
et	O
al	O
.,	O
1998	O
).	O

An	O
unresolved	O
issue	O
is	O
whether	O
the	O
expression	O
of	O
IgE	B-GP
correlates	O
with	O
active	O
infection	B-DS
and	O
/	O
or	O
invasion	O
of	O
certain	O
tissue	O
sites	O
in	O
the	O
host	O
,	O
or	O
possibly	O
mediates	O
only	O
bystander	O
allergic	O
-	O
type	O
reactions	O
such	O
as	O
infection	B-DS
-	O
related	O
rashes	O
(	O
Magnaval	O
et	O
al	O
.,	O
2006	O
).	O

Related	O
to	O
this	O
question	O
is	O
whether	O
particular	O
isotypes	O
are	O
functionally	O
important	O
in	O
tissue	O
immunity	O
,	O
for	O
example	O
by	O
trapping	O
larvae	O
or	O
activating	O
Fc	O
-	O
dependent	O
protection	O
mechanisms	O
.	O

Recent	O
analyses	O
of	O
differential	O
expression	O
profiles	O
of	O
anti	O
-	O
Toxocara	B-OG
spp	O
.	O
antibody	O
isotypes	O
,	O
studying	O
children	O
receiving	O
thiabendazole	O
therapy	O
,	O
found	O
that	O
specific	O
IgE	B-GP
and	O
eosinophilia	B-DS
declined	O
within	O
the	O
first	O
year	O
,	O
with	O
IgA	B-GP
and	O
IgG4	B-GP
falling	O
at	O
later	O
times	O
(	O
Elefant	O
et	O
al	O
.,	O
2006	O
).	O

Such	O
information	O
may	O
prove	O
useful	O
in	O
addressing	O
the	O
need	O
for	O
new	O
immunological	O
markers	O
that	O
could	O
be	O
used	O
to	O
chart	O
the	O
success	O
of	O
therapy	O
in	O
drug	O
-	O
treated	O
patients	O
.	O

Immunity	O
in	O
the	O
definitive	O
host	O

Although	O
almost	O
all	O
immunological	O
studies	O
on	O
T	B-OG
.	I-OG
canis	I-OG
have	O
centred	O
a	O
round	O
the	O
tissue	O
-	O
migrating	O
larvae	O
,	O
the	O
immune	O
response	O
of	O
the	O
final	O
canid	B-OG
host	O
to	O
intestinal	O
adult	O
worms	O
is	O
also	O
of	O
central	O
importance	O
.	O

A	O
long	O
-	O
term	O
aim	O
of	O
research	O
in	O
this	O
area	O
is	O
to	O
develop	O
an	O
effective	O
vaccine	O
against	O
canine	O
toxocariasis	B-DS
,	O
which	O
ideally	O
would	O
build	O
immunity	O
to	O
both	O
tissue	O
-	O
and	O
intestinal	O
stages	O
of	O
the	O
parasite	O
.	O

Intestinal	O
immunity	O
to	O
ascarid	O
worms	O
is	O
poorly	O
understood	O
;	O
taking	O
a	O
comparative	O
approach	O
,	O
based	O
on	O
animal	B-OG
models	O
of	O
taxonomically	O
distant	O
nematodes	B-OG
(	O
e	O
.	O
g	O
.	O
Nippostrongylus	B-OG
brasiliensis	I-OG
,	O
Trichuris	B-OG
muris	I-OG
),	O
it	O
would	O
be	O
predicted	O
that	O
Th2	O
-	O
dependent	O
mechanisms	O
act	O
to	O
expel	O
the	O
parasites	B-OG
,	O
but	O
the	O
cell	O
types	O
and	O
molecular	O
mediators	O
participating	O
in	O
expulsion	O
are	O
as	O
yet	O
unknown	O
.	O

Notably	O
,	O
it	O
has	O
been	O
reported	O
that	O
Foxp3	B-GP
+	O
regulatory	O
T	O
cells	O
are	O
more	O
numerous	O
in	O
dogs	B-OG
with	O
intestinal	O
nematode	B-DS
infections	I-DS
(	O
Junginger	O
et	O
al	O
.,	O
2012	O
),	O
suggesting	O
that	O
mucosal	O
tolerance	O
is	O
involved	O
in	O
persistence	O
of	O
infection	B-DS
.	O

Thus	O
,	O
interventional	O
strategies	O
to	O
neutralise	O
Tregs	O
could	O
promote	O
protective	O
immunity	O
,	O
as	O
has	O
been	O
reported	O
in	O
some	O
animal	B-OG
models	O
of	O
helminth	B-DS
infection	I-DS
(	O
Taylor	O
et	O
al	O
.,	O
2007	O
).	O

Immunity	O
to	O
the	O
larval	O
stage	O
is	O
similarly	O
poorly	O
understood	O
,	O
although	O
important	O
not	O
only	O
to	O
the	O
definitive	O
canid	B-OG
hosts	O
,	O
but	O
also	O
in	O
the	O
human	B-OG
setting	O
.	O

To	O
date	O
,	O
attempts	O
to	O
generate	O
protective	O
anti	O
-	O
larval	O
immunity	O
in	O
laboratory	O
rodents	B-OG
have	O
had	O
mixed	O
results	O
.	O

While	O
an	O
early	O
report	O
noted	O
that	O
immunisation	O
with	O
somatic	O
extracts	O
of	O
eggs	O
or	O
adult	O
worms	O
resulted	O
in	O
approximately	O
half	O
the	O
number	O
of	O
surviving	O
challenge	O
larvae	O
(	O
Izzat	O
and	O
Olson	O
,	O
1970	O
),	O
susceptibility	O
to	O
larval	O
infection	B-DS
was	O
unaltered	O
in	O
mice	B-OG
immunised	O
with	O
UV	O
-	O
irradiated	O
eggs	O
or	O
larval	O
ES	O
antigens	O
(	O
Abo	O
-	O
Shehada	O
et	O
al	O
.,	O
1991	O
).	O

Likewise	O
,	O
a	O
more	O
recent	O
study	O
found	O
no	O
evidence	O
of	O
protection	O
by	O
administering	O
a	O
second	O
challenge	O
of	O
larvae	O
to	O
previously	O
infected	O
mice	B-OG
,	O
other	O
than	O
they	O
were	O
more	O
likely	O
to	O
sequester	O
in	O
the	O
brain	O
(	O
Kolbeková	O
et	O
al	O
.,	O
2011	O
).	O

A	O
more	O
systematic	O
approach	O
,	O
comparing	O
immunisation	O
and	O
adjuvant	O
regimes	O
and	O
following	O
more	O
closely	O
the	O
resultant	O
immune	O
response	O
,	O
would	O
help	O
clarify	O
this	O
question	O
.	O

Toxocara	B-OG
spp	O
.	O
and	O
allergy	B-DS

Many	O
,	O
but	O
not	O
all	O
,	O
studies	O
have	O
linked	O
human	B-OG
Toxocara	B-DS
spp	I-DS
.	I-DS
infection	I-DS
with	O
exacerbation	O
of	O
allergic	B-DS
disease	I-DS
(	O
reviewed	O
by	O
Pinelli	O
and	O
Aranzamendi	O
(	O
2012	O
)).	O

Children	O
with	O
T	B-OG
.	I-OG
canis	I-OG
seroreactivity	O
have	O
been	O
reported	O
to	O
show	O
more	O
pronounced	O
IgE	B-GP
and	O
eosinophilia	B-DS
than	O
seronegative	O
individuals	O
as	O
well	O
as	O
greater	O
propensity	O
for	O
airway	O
allergic	O
symptoms	O
such	O
as	O
asthma	B-DS
(	O
Buijs	O
et	O
al	O
.,	O
1997	O
)	O
and	O
allergic	B-DS
rhinitis	I-DS
(	O
Yariktas	O
et	O
al	O
.,	O
2007	O
).	O

Mice	B-OG
infected	O
with	O
T	B-OG
.	I-OG
canis	I-OG
developed	O
compromised	O
lung	O
function	O
for	O
up	O
to	O
60	O
days	O
,	O
associated	O
with	O
bronchioalveolar	O
eosinophilia	B-DS
and	O
serum	O
IgE	B-GP
production	O
(	O
Pinelli	O
et	O
al	O
.,	O
2005	O
).	O

Moreover	O
,	O
using	O
a	O
protocol	O
in	O
mice	B-OG
which	O
induces	O
an	O
airway	O
allergic	O
response	O
to	O
the	O
model	O
antigen	O
ovalbumin	B-GP
,	O
T	B-DS
.	I-DS
canis	I-DS
infection	I-DS
prior	O
to	O
ovalbumin	B-GP
challenge	O
was	O
found	O
to	O
exacerbate	O
lung	O
pathology	O
(	O
Pinelli	O
et	O
al	O
.,	O
2008	O
).	O

On	O
a	O
broader	O
scale	O
,	O
infection	B-DS
with	O
T	B-OG
.	I-OG
canis	I-OG
might	O
predispose	O
human	B-OG
beings	O
towards	O
development	O
of	O
asthma	B-DS
(	O
Cooper	O
,	O
2008	O
).	O

Such	O
pro	O
-	O
allergic	O
effects	O
seemingly	O
run	O
counter	O
to	O
a	O
recent	O
interpretation	O
of	O
the	O
“	O
hygiene	O
hypothesis	O
”,	O
which	O
suggests	O
that	O
parasitic	O
helminths	B-OG
dampen	O
allergies	B-DS
and	O
other	O
immunopathologies	O
through	O
their	O
general	O
immune	O
suppressive	O
properties	O
(	O
Maizels	O
,	O
2005	O
).	O

However	O
,	O
it	O
is	O
important	O
to	O
recognise	O
that	O
T	B-OG
.	I-OG
canis	I-OG
is	O
adapted	O
to	O
its	O
definitive	O
host	O
rather	O
than	O
to	O
intermediate	O
or	O
accidental	O
hosts	O
such	O
as	O
the	O
human	B-OG
,	O
and	O
in	O
the	O
maladapted	O
setting	O
,	O
the	O
host	O
may	O
react	O
more	O
vigorously	O
and	O
pathologically	O
.	O

Evasion	O
of	O
the	O
immune	O
response	O

Long	O
-	O
term	O
survival	O
of	O
parasitic	O
helminths	B-OG
in	O
the	O
host	O
is	O
an	O
impressive	O
feat	O
in	O
the	O
face	O
of	O
the	O
well	O
-	O
armed	O
immune	O
response	O
,	O
which	O
mobilises	O
multiple	O
cell	O
types	O
and	O
molecular	O
mediators	O
,	O
including	O
high	O
-	O
affinity	O
antibodies	O
,	O
to	O
attack	O
invading	O
organisms	O
.	O
T	B-OG
.	I-OG
canis	I-OG
larvae	O
invade	O
from	O
the	O
host	O
intestinal	O
tract	O
and	O
disseminate	O
throughout	O
the	O
tissues	O
of	O
the	O
body	O
,	O
remaining	O
in	O
an	O
extracellular	O
state	O
,	O
generating	O
little	O
inflammatory	O
reaction	O
at	O
the	O
site	O
of	O
infection	B-DS
.	O

Therefore	O
,	O
it	O
is	O
implicit	O
that	O
T	B-OG
.	I-OG
canis	I-OG
is	O
able	O
to	O
disable	O
host	O
effector	O
mechanisms	O
in	O
an	O
extremely	O
effective	O
fashion	O
.	O

One	O
cell	O
type	O
,	O
associated	O
with	O
immunity	O
to	O
helminths	B-OG
in	O
the	O
tissues	O
,	O
is	O
the	O
eosinophil	O
(	O
Klion	O
and	O
Nutman	O
,	O
2004	O
;	O
Maizels	O
and	O
Balic	O
,	O
2004	O
),	O
which	O
is	O
able	O
to	O
exgorge	O
noxious	O
products	O
such	O
as	O
major	B-GP
basic	I-GP
protein	I-GP
,	O
as	O
well	O
as	O
generate	O
superoxides	O
(	O
through	O
eosinophil	B-GP
peroxidase	I-GP
)	O
and	O
other	O
damaging	O
free	O
radicals	O
.	O

Although	O
eosinophilia	B-DS
is	O
certainly	O
a	O
prominent	O
feature	O
of	O
toxocariasis	B-DS
,	O
as	O
indeed	O
in	O
many	O
other	O
helminth	B-DS
infections	I-DS
,	O
it	O
appears	O
that	O
T	B-OG
.	I-OG
canis	I-OG
is	O
largely	O
resistant	O
to	O
attack	O
by	O
this	O
cell	O
type	O
.	O

In	O
mice	B-OG
over	O
-	O
expressing	O
an	O
IL	B-GP
-	I-GP
5	I-GP
transgene	O
(	O
IL	O
-	O
5T	O
)	O
and	O
with	O
resultant	O
hypereosinophilia	B-DS
,	O
T	B-OG
.	I-OG
canis	I-OG
larvae	O
are	O
unharmed	O
,	O
although	O
an	O
unrelated	O
helminth	B-OG
N	B-OG
.	I-OG
brasiliensis	I-OG
is	O
eliminated	O
(	O
Dent	O
et	O
al	O
.,	O
1999	O
).	O

Notably	O
,	O
when	O
N	B-OG
.	I-OG
brasiliensis	I-OG
is	O
introduced	O
to	O
IL	O
-	O
5T	O
mice	B-OG
in	O
the	O
presence	O
of	O
T	B-OG
.	I-OG
canis	I-OG
ES	O
antigens	O
(	O
see	O
below	O
),	O
their	O
survival	O
is	O
greatly	O
enhanced	O
(	O
Giacomin	O
et	O
al	O
.,	O
2008	O
).	O

Conversely	O
,	O
in	O
IL	B-GP
-	I-GP
5	I-GP
-	O
deficient	O
mice	B-OG
there	O
is	O
no	O
change	O
in	O
larval	O
survival	O
,	O
although	O
pathology	O
in	O
the	O
lung	O
is	O
diminished	O
compared	O
to	O
wild	O
-	O
type	O
(	O
IL	B-GP
-	I-GP
5	I-GP
-	O
sufficient	O
)	O
controls	O
(	O
Takamoto	O
et	O
al	O
.,	O
1997	O
).	O

Shedding	O
of	O
the	O
surface	O
coat	O

The	O
inability	O
of	O
eosinophils	O
to	O
kill	O
T	B-OG
.	I-OG
canis	I-OG
was	O
observed	O
in	O
vitro	O
,	O
in	O
experiments	O
in	O
which	O
cells	O
and	O
larvae	O
are	O
co	O
-	O
incubated	O
.	O

While	O
in	O
the	O
presence	O
of	O
specific	O
antibodies	O
,	O
eosinophils	O
rapidly	O
adhered	O
to	O
the	O
parasite	O
surface	O
,	O
but	O
within	O
24	O
h	O
the	O
larvae	O
had	O
escaped	O
from	O
surrounding	O
cells	O
(	O
Fattah	O
et	O
al	O
.,	O
1986	O
),	O
leaving	O
the	O
eosinophils	O
still	O
attached	O
to	O
material	O
which	O
had	O
clearly	O
become	O
detached	O
from	O
the	O
surface	O
(	O
Badley	O
et	O
al	O
.,	O
1987a	O
).	O

These	O
observations	O
of	O
shedding	O
cells	O
bound	O
to	O
the	O
parasite	O
surface	O
have	O
an	O
interesting	O
link	O
to	O
electron	O
microscopic	O
observations	O
of	O
a	O
labile	O
surface	O
coat	O
from	O
the	O
larval	O
parasite	O
,	O
distal	O
to	O
and	O
separated	O
from	O
the	O
nematode	B-OG
cuticle	O
.	O

When	O
larvae	O
are	O
treated	O
with	O
a	O
lipophilic	O
stain	O
,	O
a	O
“	O
fuzzy	O
coat	O
”	O
can	O
be	O
visualised	O
,	O
10	O
–	O
20	O
nm	O
thick	O
and	O
lying	O
approximately	O
the	O
same	O
distance	O
from	O
the	O
cuticle	O
surface	O
,	O
while	O
following	O
each	O
cuticle	O
annulation	O
and	O
fold	O
(	O
Page	O
et	O
al	O
.,	O
1992b	O
).	O

The	O
fuzzy	O
coat	O
can	O
be	O
stained	O
with	O
polycationic	O
ligands	O
such	O
as	O
ferritin	B-GP
,	O
indicating	O
that	O
it	O
bears	O
an	O
overall	O
negative	O
charge	O
.	O

Notably	O
,	O
the	O
coat	O
is	O
lost	O
within	O
2	O
h	O
of	O
co	O
-	O
incubating	O
larvae	O
with	O
antibodies	O
reactive	O
to	O
the	O
surface	O
,	O
elucidating	O
the	O
physical	O
basis	O
of	O
the	O
original	O
report	O
of	O
antibody	O
shedding	O
by	O
T	B-OG
.	I-OG
canis	I-OG
larvae	O
in	O
vitro	O
(	O
Smith	O
et	O
al	O
.,	O
1981	O
).	O

While	O
the	O
first	O
observations	O
of	O
antibody	O
shedding	O
employed	O
polyclonal	O
sera	O
,	O
later	O
studies	O
confirmed	O
this	O
with	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
reagents	O
.	O

In	O
particular	O
,	O
two	O
MAbs	O
designated	O
Tcn	B-GP
-	I-GP
2	I-GP
and	O
Tcn	B-GP
-	I-GP
8	I-GP
,	O
which	O
bind	O
strongly	O
to	O
live	O
larvae	O
,	O
and	O
which	O
are	O
rapidly	O
shed	O
,	O
were	O
also	O
demonstrated	O
by	O
immuno	O
-	O
electron	O
microscopy	O
to	O
bind	O
the	O
surface	O
coat	O
(	O
Page	O
et	O
al	O
.,	O
1992b	O
).	O

Interestingly	O
,	O
the	O
same	O
antibodies	O
were	O
used	O
to	O
stain	O
sections	O
of	O
larvae	O
,	O
and	O
identified	O
two	O
distinct	O
secretory	O
bodies	O
within	O
the	O
larva	O
,	O
the	O
oesophageal	O
gland	O
opening	O
into	O
the	O
buccal	O
cavity	O
,	O
and	O
the	O
mid	O
-	O
body	O
secretory	O
column	O
which	O
is	O
a	O
ducted	O
secretory	O
pore	O
(	O
Page	O
et	O
al	O
.,	O
1992a	O
).	O

The	O
Tcn	B-GP
-	I-GP
2	I-GP
and	O
Tcn	B-GP
-	I-GP
8	I-GP
monoclonal	O
antibodies	O
which	O
bind	O
the	O
surface	O
coat	O
,	O
recognise	O
related	O
but	O
distinct	O
trisaccharide	O
glycan	O
side	O
-	O
chains	O
(	O
Schabussova	O
et	O
al	O
.,	O
2007	O
),	O
which	O
are	O
expressed	O
on	O
the	O
family	O
of	O
mucin	B-GP
polypeptides	O
,	O
principally	O
MUC	B-GP
-	I-GP
1	I-GP
,	O
-	O
2	O
and	O
-	O
3	O
collectively	O
termed	O
TES	B-GP
-	I-GP
120	I-GP
(	O
Loukas	O
et	O
al	O
.,	O
2000b	O
).	O

The	O
coat	O
and	O
the	O
secretory	O
column	O
are	O
also	O
bound	O
by	O
the	O
N	O
-	O
acetylglucosamine	O
-	O
specific	O
lectin	B-GP
,	O
Wheat	B-OG
Germ	O
Agglutinin	O
(	O
Page	O
et	O
al	O
.,	O
1992c	O
).	O

While	O
the	O
fuzzy	O
coat	O
therefore	O
seems	O
likely	O
to	O
represent	O
a	O
mucin	B-GP
-	O
and	O
glycan	O
-	O
rich	O
assembly	O
,	O
it	O
is	O
not	O
yet	O
determined	O
if	O
the	O
mucins	B-GP
are	O
further	O
covalently	O
modified	O
in	O
any	O
way	O
,	O
or	O
linked	O
to	O
other	O
molecular	O
components	O
,	O
in	O
order	O
to	O
form	O
a	O
stable	O
coat	O
structure	O
.	O

TES	O
antigens	O
and	O
immune	O
modulation	O
by	O
TES	O
antigens	O

While	O
the	O
ability	O
of	O
larvae	O
to	O
escape	O
antibody	O
and	O
cellular	O
attack	O
is	O
unusual	O
among	O
helminth	B-OG
parasites	B-OG
,	O
a	O
more	O
general	O
feature	O
is	O
modulation	O
of	O
the	O
systemic	O
immune	O
response	O
to	O
infection	B-DS
.	O

In	O
T	B-OG
.	I-OG
canis	I-OG
infected	O
mice	B-OG
,	O
the	O
pro	O
-	O
inflammatory	O
responses	O
of	O
macrophages	O
are	O
dampened	O
(	O
Kuroda	O
et	O
al	O
.,	O
2001	O
),	O
while	O
susceptibility	O
to	O
a	O
sub	O
-	O
lethal	O
dose	O
of	O
Japanese	B-OG
encephalitis	I-OG
virus	I-OG
is	O
increased	O
(	O
Gupta	O
and	O
Pavri	O
,	O
1987	O
).	O

Recent	O
work	O
has	O
reported	O
an	O
expansion	O
of	O
the	O
suppressive	O
T	O
cell	O
subset	O
of	O
Foxp3	B-GP
+	O
regulatory	O
T	O
cells	O
in	O
murine	O
toxocariasis	B-DS
(	O
Othman	O
et	O
al	O
.,	O
2011	O
),	O
which	O
may	O
underpin	O
some	O
of	O
these	O
in	O
vivo	O
effects	O
.	O

It	O
is	O
likely	O
that	O
both	O
local	O
and	O
systemic	O
effects	O
of	O
parasite	B-DS
infection	I-DS
on	O
host	O
immunity	O
are	O
mediated	O
by	O
secreted	O
products	O
,	O
such	O
as	O
the	O
TES	O
antigens	O
.	O

As	O
mentioned	O
previously	O
,	O
TES	O
can	O
inhibit	O
the	O
protective	O
effects	O
of	O
eosinophils	O
(	O
Giacomin	O
et	O
al	O
.,	O
2008	O
)	O
and	O
is	O
able	O
to	O
induce	O
recruitment	O
of	O
both	O
eosinophils	O
(	O
Sugane	O
and	O
Oshima	O
,	O
1984	O
)	O
and	O
alternatively	O
activated	O
macrophages	O
(	O
Allen	O
and	O
MacDonald	O
,	O
1998	O
).	O

However	O
,	O
TES	O
is	O
a	O
complex	O
mixture	O
of	O
differing	O
molecular	O
components	O
,	O
which	O
require	O
further	O
characterisation	O
if	O
the	O
specific	O
immunomodulatory	O
effects	O
of	O
the	O
parasite	O
are	O
to	O
be	O
understood	O
.	O

de	O
Savigny	O
(	O
1975	O
)	O
first	O
reported	O
that	O
T	B-OG
.	I-OG
canis	I-OG
larvae	O
show	O
remarkable	O
longevity	O
in	O
vitro	O
,	O
allowing	O
long	O
-	O
term	O
collection	O
of	O
ES	O
antigens	O
over	O
many	O
months	O
.	O

As	O
detailed	O
below	O
,	O
such	O
“	O
TES	O
”	O
proved	O
to	O
be	O
extremely	O
useful	O
for	O
diagnostic	O
purposes	O
.	O

Within	O
TES	O
,	O
the	O
molecular	O
components	O
were	O
first	O
described	O
by	O
their	O
molecular	O
weight	O
on	O
SDS	O
-	O
PAGE	O
analysis	O
,	O
with	O
major	O
bands	O
evident	O
at	O
26	O
,	O
32	O
,	O
45	O
,	O
55	O
,	O
70	O
,	O
120	O
and	O
400	O
kDa	O
(	O
Maizels	O
et	O
al	O
.,	O
1984	O
);	O
even	O
at	O
this	O
stage	O
the	O
extensive	O
overlap	O
between	O
surface	B-GP
proteins	I-GP
and	O
those	O
in	O
TES	O
was	O
clear	O
.	O

Subsequent	O
studies	O
of	O
TES	O
used	O
1	O
-	O
and	O
2	O
-	O
dimensional	O
SDS	O
-	O
PAGE	O
to	O
more	O
precisely	O
classify	O
components	O
(	O
Badley	O
et	O
al	O
.,	O
1987b	O
;	O
Meghji	O
and	O
Maizels	O
,	O
1986	O
),	O
together	O
with	O
techniques	O
such	O
as	O
biosynthetic	O
labelling	O
with	O
radioactive	O
amino	O
acids	O
(	O
Page	O
and	O
Maizels	O
,	O
1992	O
;	O
Sugane	O
et	O
al	O
.,	O
1985	O
).	O

A	O
high	O
degree	O
of	O
glycosylation	O
was	O
observed	O
,	O
amounting	O
to	O
∼	O
40	O
%	O
of	O
TES	O
by	O
weight	O
(	O
Meghji	O
and	O
Maizels	O
,	O
1986	O
).	O

Histological	O
sections	O
of	O
liver	O
from	O
infected	O
mice	B-OG
also	O
showed	O
that	O
TES	O
is	O
released	O
from	O
larvae	O
in	O
vivo	O
(	O
Parsons	O
et	O
al	O
.,	O
1986	O
).	O

Over	O
subsequent	O
years	O
,	O
a	O
combination	O
of	O
peptide	O
sequencing	O
(	O
Loukas	O
et	O
al	O
.,	O
1999b	O
),	O
monoclonal	O
antibody	O
binding	O
(	O
Bowman	O
et	O
al	O
.,	O
1993	O
;	O
Maizels	O
et	O
al	O
.,	O
1987	O
)	O
and	O
recombinant	O
DNA	O
techniques	O
(	O
Gems	O
et	O
al	O
.,	O
1995	O
;	O
Gems	O
and	O
Maizels	O
,	O
1996	O
;	O
Maizels	O
et	O
al	O
.,	O
2000	O
)	O
has	O
characterised	O
three	O
sets	O
of	O
TES	O
proteins	O
and	O
glycoproteins	O
(	O
TES	B-GP
-	I-GP
26	I-GP
,	O
-	O
32	O
/	O
70	O
and	O
-	O
120	O
)	O
while	O
the	O
other	O
components	O
remain	O
to	O
be	O
fully	O
characterised	O
.	O

TES	B-GP
-	I-GP
26	I-GP
:	O
Tc	O
-	O
PEB	B-GP
-	I-GP
1	I-GP

TES	B-GP
-	I-GP
26	I-GP
is	O
a	O
homologue	O
of	O
mammalian	O
phosphatidylethanolamine	B-GP
(	I-GP
PE	I-GP
)-	I-GP
binding	I-GP
protein	I-GP
and	O
was	O
renamed	O
Tc	O
-	O
PEB	B-GP
-	I-GP
1	I-GP
.	O

It	O
was	O
identified	O
initially	O
from	O
an	O
abundant	O
mRNA	O
bearing	O
at	O
its	O
5	O
′	O
end	O
the	O
conserved	O
a	O
nematode	B-OG
22	O
-	O
nt	O
spliced	O
leader	O
(	O
SL1	O
)	O
sequence	O
found	O
previously	O
in	O
Caenorhabditis	B-OG
elegans	I-OG
(	O
Krause	O
and	O
Hirsh	O
,	O
1987	O
).	O

While	O
the	O
T	B-OG
.	I-OG
canis	I-OG
PEB	B-GP
protein	O
is	O
similar	O
to	O
homologues	O
from	O
other	O
species	O
in	O
functionally	O
binding	O
PE	O
,	O
its	O
structure	O
differs	O
markedly	O
in	O
including	O
a	O
72	O
-	O
aa	O
N	O
-	O
terminal	O
extension	O
,	O
containing	O
a	O
tandemly	O
repeated	O
six	O
-	O
cysteine	O
motif	O
homologous	O
to	O
the	O
potassium	B-GP
channel	I-GP
toxin	I-GP
of	O
the	O
sea	B-OG
anemone	I-OG
,	O
Stocihactis	B-OG
helianthus	I-OG
(	O
Gems	O
et	O
al	O
.,	O
1995	O
).	O

The	O
S	B-OG
.	I-OG
helianthus	I-OG
K	O
-	O
toxin	O
(	O
ShKT	O
)	O
domain	O
figures	O
prominently	O
in	O
a	O
number	O
of	O
other	O
secreted	O
proteins	O
not	O
only	O
from	O
Toxocara	B-OG
spp	O
.,	O
but	O
also	O
from	O
other	O
nematode	B-OG
parasites	B-OG
,	O
although	O
as	O
yet	O
has	O
no	O
known	O
functional	O
role	O
.	O

TES	B-GP
-	I-GP
32	I-GP
and	O
-	O
70	O
:	O
C	B-GP
-	I-GP
type	I-GP
lectins	I-GP
(	O
CTLs	B-GP
)	O

TES	B-GP
-	I-GP
32	I-GP
(	O
Loukas	O
et	O
al	O
.,	O
1999b	O
)	O
and	O
TES	B-GP
-	I-GP
70	I-GP
(	O
Loukas	O
et	O
al	O
.,	O
2000a	O
)	O
were	O
isolated	O
by	O
matching	O
tryptic	O
peptide	O
sequences	O
from	O
gel	O
-	O
purified	O
proteins	O
to	O
an	O
EST	O
database	O
of	O
larval	O
mRNA	O
sequences	O
(	O
Tetteh	O
et	O
al	O
.,	O
1999	O
).	O

Both	O
are	O
members	O
of	O
the	O
C	B-GP
-	I-GP
type	I-GP
lectin	I-GP
family	O
;	O
hence	O
TES	B-GP
-	I-GP
32	I-GP
was	O
reassigned	O
at	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
.	O

This	O
is	O
homologous	O
to	O
mammalian	O
mannose	B-GP
-	I-GP
binding	I-GP
protein	I-GP
,	O
and	O
modelling	O
studies	O
which	O
indicated	O
that	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
does	O
indeed	O
bind	O
mannose	O
residues	O
were	O
experimentally	O
confirmed	O
(	O
Loukas	O
et	O
al	O
.,	O
1999b	O
).	O

Within	O
the	O
EST	O
database	O
were	O
two	O
related	O
sequences	O
with	O
minor	O
amino	O
acid	O
variants	O
which	O
have	O
been	O
designated	O
Tc	O
-	O
CTL	B-GP
-	I-GP
2	I-GP
and	O
-	O
3	O
.	O

A	O
near	O
-	O
identical	O
sequence	O
was	O
later	O
described	O
by	O
an	O
independent	O
group	O
as	O
a	O
proteoglycan	B-GP
core	I-GP
protein	I-GP
(	O
Yamasaki	O
et	O
al	O
.,	O
1998	O
).	O

Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
is	O
also	O
one	O
of	O
the	O
major	O
larval	O
surface	B-GP
proteins	I-GP
,	O
and	O
monoclonal	O
antibody	O
localisation	O
has	O
shown	O
that	O
it	O
is	O
expressed	O
in	O
the	O
cuticle	O
of	O
the	O
parasite	O
(	O
Page	O
et	O
al	O
.,	O
1992a	O
).	O

Whether	O
the	O
cuticular	O
form	O
bears	O
any	O
modification	O
,	O
and	O
/	O
or	O
is	O
secreted	O
directly	O
from	O
the	O
cuticle	O
into	O
the	O
larval	O
environment	O
,	O
remains	O
to	O
be	O
determined	O
.	O

Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
also	O
appears	O
to	O
be	O
well	O
-	O
conserved	O
within	O
the	O
Toxocara	B-OG
genus	O
;	O
the	O
anti	O
-	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
Mab	O
Tcn	B-GP
-	I-GP
3	I-GP
reacts	O
with	O
proteins	O
in	O
both	O
Toxocara	B-OG
cati	I-OG
(	O
Kennedy	O
et	O
al	O
.,	O
1987	O
)	O
and	O
Toxocara	B-OG
vitulorum	I-OG
(	O
Page	O
et	O
al	O
.,	O
1991	O
),	O
albeit	O
of	O
differing	O
molecular	O
weights	O
.	O

In	O
addition	O
,	O
there	O
is	O
significant	O
cross	O
-	O
reactivity	O
of	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
with	O
antibodies	O
generated	O
to	O
the	O
raccoon	B-OG
ascarid	I-OG
Baylisascaris	B-OG
procyonis	I-OG
(	O
Boyce	O
et	O
al	O
.,	O
1988	O
).	O

However	O
,	O
there	O
is	O
no	O
cross	O
-	O
reaction	O
with	O
ES	O
from	O
Toxascaris	B-OG
leonina	I-OG
(	O
Page	O
et	O
al	O
.,	O
1991	O
)	O
and	O
mice	B-OG
infected	O
with	O
Ascaris	B-OG
suum	I-OG
do	O
not	O
develop	O
serum	O
antibodies	O
to	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
.	O

TES	B-GP
-	I-GP
70	I-GP
is	O
a	O
further	O
C	B-GP
-	I-GP
type	I-GP
lectin	I-GP
,	O
now	O
referred	O
to	O
as	O
Tc	O
-	O
CTL	B-GP
-	I-GP
4	I-GP
,	O
which	O
has	O
been	O
shown	O
to	O
bind	O
to	O
canine	O
cells	O
in	O
vitro	O
.	O

Although	O
the	O
mammalian	O
ligand	O
has	O
yet	O
to	O
be	O
identified	O
,	O
this	O
is	O
the	O
first	O
instance	O
of	O
a	O
TES	O
product	O
directly	O
targeting	O
host	O
receptors	O
(	O
Loukas	O
et	O
al	O
.,	O
2000a	O
).	O

Monoclonal	O
antibodies	O
to	O
Tc	O
-	O
CTL	B-GP
-	I-GP
4	I-GP
also	O
react	O
with	O
products	O
in	O
ES	O
of	O
other	O
Toxocara	B-OG
species	O
,	O
indicating	O
that	O
secretion	O
of	O
C	B-GP
-	I-GP
type	I-GP
lectins	I-GP
might	O
be	O
a	O
shared	O
hallmark	O
of	O
this	O
genus	O
(	O
Page	O
et	O
al	O
.,	O
1991	O
).	O

TES	B-GP
-	I-GP
120	I-GP
:	O
mucins	B-GP

As	O
with	O
TES	B-GP
-	I-GP
26	I-GP
,	O
the	O
original	O
isolation	O
of	O
cDNA	O
clones	O
corresponding	O
to	O
TES	B-GP
-	I-GP
120	I-GP
antigens	O
was	O
facilitated	O
by	O
the	O
presence	O
of	O
the	O
SL1	O
trans	O
-	O
spliced	O
leader	O
sequence	O
.	O

The	O
conserved	O
sequence	O
of	O
the	O
SL1	O
permitted	O
full	O
-	O
length	O
cloning	O
,	O
without	O
the	O
requirement	O
for	O
a	O
cDNA	O
library	O
or	O
development	O
of	O
specific	O
probes	O
(	O
Gems	O
and	O
Maizels	O
,	O
1996	O
).	O

The	O
most	O
highly	O
expressed	O
gene	O
encoded	O
a	O
mucin	B-GP
sequence	O
,	O
designated	O
MUC	B-GP
-	I-GP
1	I-GP
.	O

Further	O
studies	O
established	O
that	O
T	B-OG
.	I-OG
canis	I-OG
larvae	O
express	O
a	O
set	O
of	O
mucin	B-GP
-	I-GP
like	I-GP
glycoproteins	I-GP
with	O
extensive	O
Serine	O
-	O
Threonine	O
rich	O
domains	O
which	O
act	O
as	O
sites	O
of	O
O	O
-	O
linked	O
glycosylation	O
,	O
forming	O
a	O
surface	O
“	O
fuzzy	O
coat	O
”	O
described	O
previously	O
(	O
Page	O
et	O
al	O
.,	O
1992b	O
).	O

The	O
principal	O
mucins	B-GP
are	O
MUC	B-GP
-	I-GP
1	I-GP
(	O
Gems	O
and	O
Maizels	O
,	O
1996	O
),	O
-	O
2	O
and	O
-	O
3	O
(	O
Loukas	O
et	O
al	O
.,	O
2000b	O
)	O
with	O
less	O
abundant	O
components	O
MUC	B-GP
-	I-GP
4	I-GP
and	O
-	O
5	O
(	O
Doedens	O
et	O
al	O
.,	O
2001	O
),	O
differing	O
in	O
structure	O
and	O
the	O
relative	O
proportions	O
of	O
Serine	O
or	O
Threonine	O
residues	O
(	O
Loukas	O
et	O
al	O
.,	O
2000b	O
).	O

Most	O
strikingly	O
,	O
all	O
contain	O
tandemly	O
repeated	O
ShKT	O
domains	O
at	O
either	O
or	O
both	O
of	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
,	O
flanking	O
the	O
central	O
mucin	B-GP
core	O
.	O

Glycans	O
of	O
T	B-OG
.	I-OG
canis	I-OG

Initial	O
chemical	O
analysis	O
of	O
TES	O
revealed	O
a	O
high	O
content	O
of	O
galactose	O
and	O
N	O
-	O
acetylgalactosamine	O
,	O
amounting	O
to	O
∼	O
40	O
%	O
by	O
total	O
weight	O
of	O
the	O
secreted	O
products	O
(	O
Meghji	O
and	O
Maizels	O
,	O
1986	O
).	O

However	O
,	O
there	O
is	O
only	O
a	O
limited	O
degree	O
of	O
N	O
-	O
glycoslyation	O
,	O
of	O
CTL	B-GP
-	I-GP
1	I-GP
and	O
-	O
4	O
,	O
as	O
revealed	O
by	O
molecular	O
weight	O
shifts	O
following	O
N	B-GP
-	I-GP
glycanase	I-GP
digestion	O
of	O
total	O
TES	O
products	O
.	O

In	O
contrast	O
,	O
O	O
-	O
linked	O
sugars	O
represent	O
the	O
majority	O
of	O
the	O
released	O
carbohydrates	O
,	O
mostly	O
linked	O
to	O
the	O
mucin	B-GP
families	O
(	O
MUC	B-GP
-	I-GP
1	I-GP
to	O
-	O
5	O
).	O

Mass	O
spectrometry	O
of	O
the	O
O	O
-	O
linked	O
sugars	O
determined	O
them	O
to	O
be	O
two	O
related	O
trisaccharides	O
,	O
2	O
-	O
O	O
-	O
Me	O
-	O
Fucα1	O
-	O
2	O
(	O
4	O
-	O
O	O
-	O
Me	O
)	O
Galβ1	O
-	O
3	O
-	O
GalNAc	O
,	O
and	O
2	O
-	O
O	O
-	O
Me	O
-	O
Fucα1	O
-	O
2Galβ1	O
-	O
3GalNAc	O
,	O
differing	O
only	O
in	O
whether	O
the	O
central	O
galactose	O
sugar	O
bears	O
an	O
O	O
-	O
methyl	O
side	O
chain	O
(	O
Khoo	O
et	O
al	O
.,	O
1991	O
).	O

Notably	O
,	O
the	O
non	O
-	O
O	O
-	O
methylated	O
form	O
of	O
this	O
trisaccharide	O
is	O
identical	O
to	O
the	O
human	B-OG
blood	O
group	O
H	B-GP
antigen	I-GP
,	O
providing	O
a	O
structural	O
explanation	O
for	O
the	O
expression	O
of	O
blood	O
group	O
specificities	O
by	O
T	B-OG
.	I-OG
canis	I-OG
(	O
Smith	O
et	O
al	O
.,	O
1983	O
).	O

Chemical	O
synthesis	O
of	O
the	O
Toxocara	B-OG
spp	O
.-	O
specific	O
glycan	O
structures	O
(	O
Amer	O
et	O
al	O
.,	O
2001	O
)	O
provided	O
material	O
for	O
ELISA	O
with	O
monoclonal	O
antibodies	O
and	O
human	B-OG
sera	O
(	O
Schabussova	O
et	O
al	O
.,	O
2007	O
).	O

This	O
confirmed	O
that	O
the	O
species	O
-	O
specific	O
Mab	O
,	O
Tcn	B-GP
-	I-GP
2	I-GP
,	O
recognises	O
the	O
mono	O
-	O
methylated	O
trisaccharide	O
,	O
while	O
the	O
shared	O
epitope	O
present	O
in	O
other	O
Toxocara	B-OG
species	O
is	O
the	O
dimethylated	O
structure	O
(	O
Schabussova	O
et	O
al	O
.,	O
2007	O
).	O

Subsequently	O
,	O
synthesis	O
of	O
the	O
glycan	O
Fucα1	O
-	O
2Galβ1	O
-	O
3GalNAc	O
,	O
omitting	O
methylation	O
of	O
either	O
the	O
terminal	O
fucose	O
or	O
the	O
intermediate	O
galactose	O
,	O
was	O
used	O
to	O
demonstrate	O
loss	O
of	O
antibody	O
binding	O
,	O
formally	O
confirming	O
that	O
the	O
Me	O
-	O
Gal	O
residue	O
is	O
essential	O
for	O
this	O
reaction	O
(	O
Koizumi	O
et	O
al	O
.,	O
2012	O
).	O

In	O
addition	O
,	O
analysis	O
of	O
the	O
N	O
-	O
linked	O
glycan	O
species	O
in	O
TES	O
antigens	O
has	O
been	O
undertaken	O
,	O
identifying	O
a	O
dominant	O
and	O
relatively	O
simple	O
biantennary	O
Man2Man	O
-	O
GlcNAc	O
-	O
GlcNAc	O
side	O
chain	O
(	O
Khoo	O
et	O
al	O
.,	O
1993	O
).	O

Immuno	O
-	O
diagnosis	O

The	O
original	O
reports	O
from	O
De	O
Savigny	O
(	O
de	O
Savigny	O
and	O
Tizard	O
,	O
1977	O
;	O
de	O
Savigny	O
et	O
al	O
.,	O
1979	O
)	O
provided	O
a	O
breakthrough	O
for	O
immuno	O
-	O
diagnosis	O
of	O
toxocariasis	B-DS
,	O
as	O
the	O
sensitivity	O
and	O
specificity	O
of	O
TES	O
in	O
assays	O
such	O
as	O
ELISA	O
and	O
Western	O
Blot	O
proved	O
to	O
be	O
far	O
superior	O
to	O
use	O
of	O
whole	O
worm	O
extracts	O
(	O
Van	O
Knapen	O
et	O
al	O
.,	O
1983	O
).	O

Indeed	O
,	O
the	O
use	O
of	O
TES	O
has	O
been	O
successfully	O
translated	O
into	O
a	O
commercial	O
diagnostic	O
kit	O
(	O
Jacquier	O
et	O
al	O
.,	O
1991	O
).	O

Nevertheless	O
,	O
the	O
sensitivity	O
and	O
specificity	O
of	O
TES	O
-	O
based	O
immunodiagnostic	O
tests	O
vary	O
around	O
the	O
90	O
%	O
level	O
,	O
and	O
there	O
are	O
concerns	O
that	O
the	O
presence	O
of	O
blood	O
group	O
-	O
like	O
or	O
other	O
cross	O
-	O
reactive	O
carbohydrates	O
could	O
be	O
responsible	O
for	O
a	O
number	O
of	O
false	O
-	O
positive	O
results	O
(	O
Smith	O
et	O
al	O
.,	O
1984	O
,	O
2009	O
).	O

The	O
blood	O
group	O
-	O
like	O
antigens	O
are	O
more	O
abundant	O
on	O
higher	O
molecular	O
-	O
weight	O
TES	O
components	O
(	O
TES	B-GP
-	I-GP
120	I-GP
and	O
TES	B-GP
-	I-GP
400	I-GP
),	O
and	O
therefore	O
a	O
Western	O
blotting	O
procedure	O
to	O
assay	O
human	B-OG
antibodies	O
to	O
the	O
lower	O
molecular	O
weight	O
TES	O
components	O
(	O
TES	B-GP
-	I-GP
26	I-GP
and	O
TES	B-GP
-	I-GP
32	I-GP
)	O
has	O
also	O
been	O
developed	O
(	O
Magnaval	O
et	O
al	O
.,	O
1991	O
,	O
2002	O
).	O

Recombinant	O
proteins	O
are	O
now	O
being	O
developed	O
for	O
detection	O
of	O
specific	O
antibodies	O
for	O
toxocariasis	B-DS
.	O

The	O
TES	B-GP
-	I-GP
32	I-GP
protein	O
(	O
which	O
corresponds	O
to	O
the	O
C	B-GP
-	I-GP
type	I-GP
lectin	I-GP
CTL	B-GP
-	I-GP
1	I-GP
(	O
Loukas	O
et	O
al	O
.,	O
1999b	O
))	O
was	O
shown	O
to	O
be	O
detected	O
by	O
serum	O
antibodies	O
from	O
all	O
9	O
toxocariasis	B-DS
patients	O
tested	O
.	O

In	O
addition	O
,	O
sera	O
from	O
animals	B-OG
carrying	O
T	B-DS
.	I-DS
cati	I-DS
infection	I-DS
were	O
also	O
reactive	O
,	O
reflecting	O
the	O
cross	O
-	O
reactivity	O
of	O
this	O
protein	O
between	O
Toxocara	B-OG
species	O
(	O
Kennedy	O
et	O
al	O
.,	O
1987	O
).	O

In	O
a	O
standard	O
ELISA	O
assay	O
,	O
some	O
43	O
%	O
of	O
sera	O
from	O
other	O
helminth	B-DS
infections	I-DS
cross	O
-	O
reacted	O
with	O
whole	O
TES	O
,	O
but	O
this	O
was	O
reduced	O
to	O
2	O
%	O
when	O
tested	O
against	O
recombinant	O
CTL	B-GP
-	I-GP
1	I-GP
adsorbed	O
at	O
an	O
optimal	O
antigen	O
concentration	O
(	O
Yamasaki	O
et	O
al	O
.,	O
2000	O
).	O

In	O
a	O
subsequent	O
evaluation	O
,	O
sera	O
from	O
26	O
/	O
215	O
(	O
12	O
%)	O
of	O
children	O
from	O
Pernambuco	O
,	O
Brazil	O
,	O
recognised	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
(	O
TES	B-GP
-	I-GP
32	I-GP
)	O
(	O
De	O
Andrade	O
Lima	O
Coêlho	O
et	O
al	O
.,	O
2005	O
).	O

It	O
should	O
be	O
noted	O
that	O
in	O
both	O
studies	O
,	O
recombinant	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
was	O
produced	O
as	O
inclusion	O
bodies	O
in	O
bacteria	O
and	O
required	O
8	O
M	O
urea	O
solubilisation	O
,	O
indicating	O
that	O
a	O
correctly	O
folded	O
version	O
of	O
the	O
same	O
antigen	O
may	O
show	O
increased	O
immunoreactivity	O
as	O
this	O
would	O
detect	O
conformational	O
as	O
well	O
as	O
linear	O
epitopes	O
.	O

Most	O
diagnostic	O
serological	O
tests	O
measure	O
total	O
IgG	B-GP
antibodies	O
.	O

In	O
a	O
comparative	O
study	O
to	O
test	O
an	O
IgG4	B-GP
-	O
specific	O
assay	O
,	O
it	O
was	O
noted	O
that	O
sensitivity	O
was	O
markedly	O
reduced	O
(	O
as	O
many	O
patients	O
do	O
not	O
mount	O
an	O
IgG4	B-GP
response	O
)	O
but	O
specificity	O
was	O
greatly	O
enhanced	O
compared	O
to	O
measuring	O
total	O
IgG	B-GP
(	O
Noordin	O
et	O
al	O
.,	O
2005	O
).	O

These	O
authors	O
went	O
on	O
to	O
develop	O
an	O
IgG4	B-GP
-	O
specific	O
diagnostic	O
assay	O
employing	O
three	O
recombinant	O
antigens	O
(	O
Tc	O
-	O
PEB	B-GP
-	I-GP
1	I-GP
or	O
TES	B-GP
-	I-GP
26	I-GP
,	O
Tc	O
-	O
CTL	B-GP
-	I-GP
1	I-GP
or	O
TES	B-GP
-	I-GP
32	I-GP
also	O
named	O
TES	O
-	O
30USM	O
,	O
and	O
Tc	O
-	O
MUC	B-GP
-	I-GP
1	I-GP
or	O
TES120	B-GP
).	O

While	O
none	O
of	O
the	O
antigens	O
individually	O
showed	O
100	O
%	O
specificity	O
,	O
a	O
combination	O
of	O
the	O
three	O
was	O
able	O
to	O
detect	O
all	O
samples	O
serologically	O
reactive	O
to	O
native	O
TES	O
,	O
and	O
showed	O
cross	O
-	O
reactivity	O
with	O
only	O
2	O
–	O
4	O
%	O
of	O
serum	O
samples	O
from	O
other	O
infections	B-DS
(	O
Mohamad	O
et	O
al	O
.,	O
2009	O
).	O

As	O
well	O
as	O
recombinant	O
proteins	O
,	O
the	O
specific	O
glycan	O
structures	O
associated	O
with	O
T	B-OG
.	I-OG
canis	I-OG
also	O
hold	O
promise	O
for	O
immuno	O
-	O
diagnosis	O
.	O

It	O
was	O
found	O
that	O
sera	O
from	O
human	B-OG
toxocariasis	B-DS
patients	O
reacted	O
to	O
the	O
di	O
-	O
O	O
-	O
methylated	O
structure	O
2	O
-	O
O	O
-	O
Me	O
-	O
Fucα1	O
-	O
2	O
(	O
4	O
-	O
O	O
-	O
Me	O
)	O
Galβ1	O
-	O
3	O
-	O
GalNAc	O
,	O
although	O
no	O
antibodies	O
were	O
detected	O
to	O
the	O
species	O
-	O
specific	O
monomethylated	O
form	O
Schabussova	O
et	O
al	O
.	O
(	O
2007	O
).	O

As	O
is	O
often	O
the	O
case	O
with	O
glycan	O
epitopes	O
,	O
human	B-OG
antibodies	O
were	O
restricted	O
to	O
the	O
IgM	B-GP
and	O
IgG2	O
isotypes	O
.	O

Using	O
polyclonal	O
antibodies	O
against	O
TES	O
in	O
a	O
sandwich	O
ELISA	O
,	O
circulating	O
parasite	O
antigens	O
can	O
be	O
detected	O
in	O
the	O
serum	O
of	O
infected	O
dogs	B-OG
,	O
particularly	O
pups	O
(	O
Matsumura	O
et	O
al	O
.,	O
1984	O
),	O
and	O
in	O
serum	O
of	O
children	O
with	O
suspected	O
infection	B-DS
(	O
Luo	O
et	O
al	O
.,	O
1999	O
).	O

Similarly	O
,	O
circulating	O
antigen	O
could	O
be	O
found	O
in	O
both	O
human	B-OG
and	O
experimental	O
mouse	B-OG
serum	O
samples	O
,	O
with	O
the	O
monoclonal	O
antibody	O
Tcn	B-GP
-	I-GP
2	I-GP
which	O
recognises	O
a	O
species	O
-	O
specific	O
repetitive	O
epitope	O
that	O
facilitates	O
detection	O
(	O
Gillespie	O
et	O
al	O
.,	O
1993	O
;	O
Robertson	O
et	O
al	O
.,	O
1988	O
).	O

Genomics	O
,	O
transcriptomics	O
and	O
other	O
molecular	O
analyses	O

Despite	O
the	O
importance	O
of	O
T	B-OG
.	I-OG
canis	I-OG
in	O
both	O
veterinary	O
and	O
zoonotic	O
contexts	O
,	O
there	O
is	O
relatively	O
little	O
information	O
available	O
at	O
the	O
genomic	O
and	O
transcriptomic	O
levels	O
.	O

Currently	O
,	O
the	O
parasite	O
genome	O
has	O
yet	O
to	O
be	O
sequenced	O
.	O

However	O
,	O
the	O
14	O
,	O
162	O
-	O
bp	O
mitochondrial	O
sequence	O
has	O
been	O
published	O
(	O
Jex	O
et	O
al	O
.,	O
2008	O
),	O
and	O
the	O
273	O
-	O
Mb	O
genome	O
sequence	O
of	O
the	O
related	O
parasite	O
A	B-OG
.	I-OG
suum	I-OG
was	O
recently	O
reported	O
(	O
Jex	O
et	O
al	O
.,	O
2011	O
).	O

Similarly	O
,	O
the	O
T	B-OG
.	I-OG
canis	I-OG
transcriptome	O
is	O
relatively	O
under	O
-	O
explored	O
(	O
Gasser	O
,	O
2013	O
).	O

Over	O
10	O
years	O
ago	O
a	O
small	O
-	O
scale	O
EST	O
project	O
on	O
larval	O
cDNAs	O
was	O
able	O
to	O
identify	O
128	O
distinct	O
genes	O
and	O
despite	O
its	O
limited	O
scope	O
,	O
this	O
study	O
characterised	O
most	O
of	O
the	O
major	O
secreted	O
antigens	O
and	O
a	O
number	O
of	O
novel	O
gene	O
families	O
,	O
many	O
of	O
which	O
are	O
listed	O
in	O
Table	O
1	O
(	O
Tetteh	O
et	O
al	O
.,	O
1999	O
).	O

A	O
further	O
1975	O
gene	O
clusters	O
were	O
assembled	O
from	O
∼	O
5000	O
Sanger	O
sequencing	O
reads	O
and	O
can	O
be	O
searched	O
at	O
http	O
://	O
nematode	B-OG
.	O
net	O
.	O

More	O
recently	O
,	O
a	O
female	O
adult	O
cDNA	O
sequencing	O
effort	O
yielded	O
79	O
genes	O
,	O
including	O
2	O
C	B-GP
-	I-GP
type	I-GP
lectins	I-GP
and	O
an	O
As16	O
homologue	O
(	O
Zhou	O
et	O
al	O
.,	O
2011	O
).	O

However	O
,	O
most	O
of	O
the	O
identified	O
genes	O
have	O
yet	O
to	O
be	O
annotated	O
or	O
deposited	O
in	O
public	O
databases	O
,	O
with	O
NCBI	O
for	O
example	O
holding	O
only	O
28	O
distinct	O
non	O
-	O
mitochondrial	O
/	O
ribosomal	O
protein	O
gene	O
sequences	O
at	O
the	O
time	O
of	O
writing	O
.	O

Much	O
more	O
ambitious	O
datasets	O
are	O
required	O
to	O
establish	O
the	O
protein	O
repertoire	O
of	O
T	B-OG
.	I-OG
canis	I-OG
and	O
to	O
identify	O
patterns	O
of	O
stage	O
-	O
specific	O
protein	O
expression	O
in	O
the	O
parasite	O
life	O
cycle	O
.	O

In	O
the	O
last	O
few	O
years	O
,	O
a	O
new	O
class	O
of	O
biological	O
regulatory	O
molecules	O
has	O
been	O
defined	O
with	O
the	O
discovery	O
of	O
small	O
(∼	O
22	O
-	O
nucleotide	O
)	O
RNA	O
species	O
which	O
bind	O
to	O
and	O
inhibit	O
translation	O
of	O
target	O
mRNAs	O
and	O
mediate	O
their	O
degradation	O
within	O
the	O
cell	O
.	O

Most	O
documented	O
cases	O
of	O
miRNA	O
binding	O
are	O
to	O
the	O
3	O
′	O
untranslated	O
region	O
(	O
3	O
′	O
UTR	O
)	O
downstream	O
of	O
the	O
translational	O
stop	O
codon	O
.	O

Abundant	O
miRNAs	O
have	O
been	O
described	O
in	O
several	O
nematode	B-OG
species	O
(	O
Chen	O
et	O
al	O
.,	O
2011	O
;	O
Poole	O
et	O
al	O
.,	O
2010	O
;	O
Winter	O
et	O
al	O
.,	O
2012	O
),	O
most	O
notably	O
the	O
free	O
-	O
living	O
worm	O
C	B-OG
.	I-OG
elegans	I-OG
,	O
which	O
provides	O
well	O
-	O
characterised	O
conserved	O
sequences	O
such	O
as	O
let	O
-	O
7	O
(	O
Ambros	O
et	O
al	O
.,	O
2003	O
;	O
Hammell	O
et	O
al	O
.,	O
2009	O
).	O

Although	O
no	O
miRNAs	O
have	O
yet	O
been	O
described	O
in	O
T	B-OG
.	I-OG
canis	I-OG
,	O
it	O
had	O
been	O
noted	O
that	O
4	O
abundant	O
novel	O
transcript	O
(	O
ANT	O
)	O
genes	O
from	O
the	O
larval	O
stage	O
shared	O
highly	O
similar	O
3	O
′	O
UTR	O
sequences	O
despite	O
dissimilar	O
coding	O
sequences	O
(	O
Tetteh	O
et	O
al	O
.,	O
1999	O
).	O

Interestingly	O
,	O
in	O
the	O
larval	O
parasite	O
,	O
no	O
evidence	O
of	O
proteins	O
corresponding	O
to	O
the	O
ANT	O
genes	O
was	O
found	O
,	O
indicating	O
that	O
either	O
gene	O
transcription	O
or	O
mRNA	O
translation	O
was	O
suppressed	O
within	O
the	O
arrested	O
stage	O
.	O

Within	O
the	O
3	O
′	O
UTR	O
tracts	O
of	O
each	O
transcript	O
were	O
motifs	O
similar	O
to	O
those	O
targeted	O
in	O
C	B-OG
.	I-OG
elegans	I-OG
by	O
let	O
-	O
7	O
,	O
and	O
when	O
the	O
3	O
′	O
UTR	O
of	O
a	O
T	B-OG
.	I-OG
canis	I-OG
ANT	O
gene	O
was	O
inserted	O
downstream	O
of	O
a	O
GFP	B-GP
construct	O
in	O
transgenic	O
C	B-OG
.	I-OG
elegans	I-OG
,	O
suppression	O
of	O
gene	O
expression	O
was	O
achieved	O
(	O
Callister	O
et	O
al	O
.,	O
2008	O
).	O

Thus	O
,	O
although	O
the	O
involvement	O
of	O
canonical	O
miRNA	O
mechanisms	O
in	O
control	O
of	O
larval	O
gene	O
expression	O
has	O
yet	O
to	O
be	O
directly	O
demonstrated	O
,	O
these	O
studies	O
strongly	O
suggest	O
that	O
this	O
is	O
the	O
case	O
.	O

Future	O
prospects	O
and	O
priorities	O

Expanding	O
our	O
understanding	O
of	O
immune	O
recognition	O
and	O
evasion	O
by	O
T	B-OG
.	I-OG
canis	I-OG
is	O
a	O
priority	O
if	O
we	O
are	O
to	O
appropriately	O
manage	O
both	O
human	B-OG
and	O
veterinary	O
disease	O
.	O

Molecular	O
studies	O
to	O
date	O
have	O
identified	O
key	O
products	O
which	O
are	O
already	O
being	O
used	O
in	O
new	O
diagnostic	O
assays	O
,	O
and	O
doubtless	O
further	O
refinement	O
will	O
lead	O
to	O
the	O
replacement	O
of	O
native	O
TES	O
as	O
the	O
principal	O
diagnostic	O
reagent	O
.	O

Beyond	O
this	O
very	O
necessary	O
innovation	O
,	O
two	O
general	O
and	O
interrelated	O
areas	O
of	O
research	O
need	O
to	O
be	O
addressed	O
:	O
by	O
what	O
molecular	O
means	O
does	O
T	B-OG
.	I-OG
canis	I-OG
suppress	O
host	O
immunity	O
,	O
and	O
how	O
can	O
we	O
intervene	O
to	O
provide	O
immunological	O
protection	O
in	O
either	O
or	O
both	O
the	O
definitive	O
and	O
paratenic	O
host	O
?	O

These	O
questions	O
should	O
spotlight	O
the	O
highly	O
evolved	O
state	O
of	O
immune	O
evasion	O
by	O
T	B-OG
.	I-OG
canis	I-OG
,	O
with	O
every	O
probability	O
of	O
defining	O
new	O
immunomodulatory	O
molecules	O
.	O

In	O
this	O
way	O
,	O
future	O
work	O
can	O
pave	O
the	O
way	O
for	O
rational	O
immunological	O
tools	O
,	O
most	O
importantly	O
vaccines	O
for	O
use	O
in	O
canid	B-OG
species	O
,	O
to	O
mimimise	O
,	O
if	O
not	O
altogether	O
eradicate	O
,	O
this	O
important	O
infection	B-DS
.	O

Conflict	O
of	O
interest	O

None	O
.	O

Defined	O
proteins	O
of	O
Toxocara	O
canis	O
.	O

Abbreviation	O

Name	O

TES	O
component	O
if	O
applicable	O

Accession	O
number	O
(	O
s	O
)	O

Length	O
(	O
incl	O
signal	O
sequence	O
if	O
present	O
)	O

Notes	O

Reference	O

Tc	O
-	O
ANT	O
-	O
3	O

Abundant	O
novel	O
transcript	O
-	O
3	O

EU792508	O
;	O
ACF19852	O

271	O
aa	O

Callister	O
et	O
al	O
.	O
(	O
2008	O
)	O

Tc	O
-	O
ANT	O
-	O
5	O

Abundant	O
novel	O
transcript	O
-	O
5	O

EU792509	O
;	O
ACF19853	O

489	O
aa	O

Callister	O
et	O
al	O
.	O
(	O
2008	O
)	O

Tc	O
-	O
ANT	O
-	O
30	O

Abundant	O
novel	O
transcript	O
-	O
30	O

EU792510	O
;	O
ACF19854	O

843	O
aa	O

Callister	O
et	O
al	O
.	O
(	O
2008	O
)	O

Tc	O
-	O
ANT	O
-	O
34	O

Abundant	O
novel	O
transcript	O
-	O
34	O

EU792511	O
;	O
ACF19855	O

608	O
aa	O

Callister	O
et	O
al	O
.	O
(	O
2008	O
)	O

Tc	O
-	O
AQP	O
-	O
1	O

Aquaporin	O

AAC32826	O

310	O
aa	O

Loukas	O
et	O
al	O
.	O
(	O
1999a	O
)	O

Tc	O
-	O
ARK	O
-	O
1	O

Arginine	O
kinase	O

ABK76312	O
;	O
AFJ95132	O

Unpublished	O

Tc	O
-	O
CPL	O
-	O
1	O

Cathepsin	O
L	O
-	O
like	O
cysteine	O
protease	O

AAC48340	O

360	O
aa	O

Loukas	O
et	O
al	O
.	O
(	O
1998	O
)	O

Tc	O
-	O
CPZ	O
-	O
1	O

Cathepsin	O
Z	O
-	O
like	O
cysteine	O
protease	O

AF143817	O

307	O
aa	O

Falcone	O
et	O
al	O
.	O
(	O
2000	O
)	O

Tc	O
-	O
CTL	O
-	O
1	O

C	O
-	O
type	O
lectin	O
-	O
1	O

TES	O
-	O
32	O

AF041023	O

219	O
aa	O

Binds	O
mannose	O

Loukas	O
et	O
al	O
.	O
(	O
1999b	O
)	O

Proteoglycan	O
core	O
protein	O

AB009305	O

219	O
aa	O

Differs	O
by	O
3	O
aa	O
from	O
above	O

Yamasaki	O
et	O
al	O
.	O
(	O
1998	O
)	O

Tc	O
-	O
CTL	O
-	O
2	O

C	O
-	O
type	O
lectin	O
-	O
2	O

–	O

219	O
aa	O

17	O
%	O
aa	O
divergence	O
from	O
CTL	O
-	O
1	O

Tetteh	O
et	O
al	O
.	O
(	O
1999	O
)	O

Tc	O
-	O
CTL	O
-	O
3	O

C	O
-	O
type	O
lectin	O
-	O
3	O

–	O

220	O
aa	O

13	O
%	O
aa	O
divergence	O
from	O
CTL	O
-	O
1	O

Tetteh	O
et	O
al	O
.	O
(	O
1999	O
)	O

Tc	O
-	O
CTL	O
-	O
4	O

C	O
-	O
type	O
lectin	O
-	O
4	O

TES	O
-	O
70	O

AF126830	O

288	O
aa	O

Binds	O
canine	O
cell	O
surface	O

Loukas	O
et	O
al	O
.	O
(	O
2000a	O
)	O

Tc	O
-	O
GLB	O
-	O
1	O

Pseudocoelomic	O
globin	O

AAL56430	O
;	O
AAL58703	O
;	O
AAL58704	O

171	O
aa	O

Minor	O
sequence	O
variants	O

Unpublished	O

Tc	O
-	O
GLB	O
-	O
2	O

Intracellular	O
globin	O

AAL56428	O
;	O
AAL56429	O

153	O
aa	O

∼	O
50	O
%	O
identity	O
to	O
GLB	O
-	O
1	O

Unpublished	O

Tc	O
-	O
LDH	O
-	O
1	O

Lactate	O
dehydrogenase	O

AAB07368	O

92	O
aa	O

Partial	O
sequence	O

Unpubished	O

Tc	O
-	O
MUC	O
-	O
1	O

Mucin	O
-	O
1	O

TES	O
-	O
120	O

AAB05820	O
;	O
U39815	O

176	O
aa	O

15	O
.	O
7	O
kDa	O
Serine	O
-	O
rich	O
peptide	O
backbone	O
with	O
2	O
ShKT	O
domains	O
,	O
39	O
.	O
7	O
kDa	O
total	O
mass	O
;	O
120	O
kDa	O
apparent	O
mobility	O
on	O
SDS	O
-	O
PAGE	O

Gems	O
and	O
Maizels	O
(	O
1996	O
)	O

Tc	O
-	O
MUC	O
-	O
2	O

Mucin	O
-	O
2	O

TES	O
-	O
120	O

AF167707	O

182	O
aa	O

16	O
.	O
2	O
kDa	O
peptide	O
with	O
2	O
ShKT	O
domains	O
;	O
47	O
.	O
8	O
kDa	O
total	O
.	O

Loukas	O
et	O
al	O
.	O
(	O
2000b	O
)	O

Tc	O
-	O
MUC	O
-	O
3	O

Mucin	O
-	O
3	O

TES	O
-	O
120	O

AF167708	O

269	O
aa	O

26	O
.	O
0	O
kDa	O
threonine	O
-	O
rich	O
peptide	O
with	O
4	O
ShKT	O
domains	O
,	O
45	O
.	O
0	O
kDa	O
total	O
.	O

Loukas	O
et	O
al	O
.	O
(	O
2000b	O
)	O

Tc	O
-	O
MUC	O
-	O
4	O

Mucin	O
-	O
4	O

TES	O
-	O
120	O

AF167709	O

191	O
aa	O

26	O
.	O
0	O
kDa	O
threonine	O
-	O
rich	O
peptide	O
with	O
4	O
ShKT	O
domains	O
,	O
45	O
.	O
0	O
kDa	O
total	O
.	O

Tetteh	O
et	O
al	O
.	O
(	O
1999	O
)	O

Tc	O
-	O
MUC	O
-	O
5	O

Mucin	O
-	O
5	O

AF167710	O

316	O
aa	O

26	O
.	O
0	O
kDa	O
threonine	O
-	O
rich	O
peptide	O
with	O
4	O
ShKT	O
domains	O
,	O
45	O
.	O
0	O
kDa	O
total	O
.	O

Doedens	O
et	O
al	O
.	O
(	O
2001	O
)	O

Tc	O
-	O
MHC	O
-	O
1	O

Myosin	O
heavy	O
chain	O

CAC28360	O

1814	O
aa	O

Obwaller	O
et	O
al	O
.	O
(	O
2001	O
)	O

Tc	O
-	O
MLC	O
-	O
1	O

Myosin	O
light	O
chain	O

U25057	O

148	O
aa	O

Unpublished	O

Tc	O
-	O
NPA	O
-	O
1	O

Nematode	O
polyprotein	O

BAA14015	O
;	O
AAD01628	O
;	O
AAB26196	O

140	O
aa	O

Fragments	O
of	O
longer	O
polyprotein	O

Christie	O
et	O
al	O
.	O
(	O
1993	O
)	O
and	O
unpublished	O

Tc	O
-	O
PEB	O
-	O
1	O

Phosphatidylethanolamine	O
-	O
binding	O
protein	O

TES	O
-	O
26	O

P54190	O
,	O
U29761	O

262	O
aa	O

PE	O
-	O
binding	O
domain	O
fused	O
with	O
2	O
ShKT	O
domains	O

Gems	O
et	O
al	O
.	O
(	O
1995	O
)	O

Tc	O
-	O
PRO	O
-	O
1	O

Prohibitin	O

AAB53231	O

274	O
aa	O

Loukas	O
and	O
Maizels	O
(	O
1998	O
)	O

Tc	O
-	O
SLO	O
-	O
1	O

Calcium	O
activated	O
channel	O

ACJ64718	O

1123	O
aa	O

Unpublished	O

Tc	O
-	O
SOD	O
-	O
1	O

Cu	O
–	O
Zn	O
superoxide	O
dismutase	O

AAB00227	O

190	O
aa	O

Unpublished	O

